文献速递消化系统肿瘤

S-1为基础治疗对比5-氟尿嘧啶或卡培他滨为基础治疗在转移性结直肠癌患者中的随机II/III期试验的系统综述与非劣效性Meta分析

Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer.
PubMed 文献 · Eur J Cancer · 2022-03-10

该系统综述与非劣效性Meta分析纳入10项随机试验共2117例转移性结直肠癌患者,比较S-1为基础方案与5-氟尿嘧啶或卡培他滨为基础方案的疗效。结果显示S-1组在无进展生存期(HR 0.95,99%CI 0.83-1.08)非劣效于对照组,总生存期(HR 0.93,99%CI 0.81-1.07)和客观缓解率(RR 1.06,99%CI 0.90-1.24)至少同等有效。结论支持S-1用于对5-FU/卡培他滨不耐受的mCRC患者。

要点

  • S-1为基础治疗在PFS上非劣效于5-FU/卡培他滨(HR 0.95,99%CI 0.83-1.08,CI上限低于预设非劣效界值1.25)。
  • S-1组OS(HR 0.93,99%CI 0.81-1.07)与ORR(RR 1.06,99%CI 0.90-1.24)至少与对照组同等有效。
  • 数据支持S-1用于对5-FU/卡培他滨为基础治疗不耐受的mCRC患者。

核心结论

  • S-1为基础治疗在mCRC的PFS上非劣效于5-FU/卡培他滨为基础治疗,在ORR和OS上至少同等有效。
  • 这些数据支持S-1用于对5-FU/卡培他滨为基础治疗不耐受的mCRC患者。

研究设计与样本

  • 系统综述与非劣效性Meta分析,检索MEDLINE、Embase、Cochrane Central Register of Controlled Trials和Opengrey截至2021年5月的随机临床试验。
  • 纳入10项研究共2117例患者,其中6项报告PFS和OS数据,10项报告ORR数据。
  • 按治疗线分层合并效应量,采用99%置信区间;PFS预设非劣效界值(ΔNI)为1.25。

主要发现

  • S-1为基础治疗对比5-FU/卡培他滨为基础治疗的PFS:HRtotal 0.95(99%CI 0.83-1.08),CI上限远低于ΔNI 1.25。
  • OS:HRtotal 0.93(99%CI 0.81-1.07)。
  • ORR:RRtotal 1.06(99%CI 0.90-1.24)。

临床怎么用

  • 原文结论支持S-1用于对5-FU/卡培他滨为基础治疗不耐受的mCRC患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: S-1 is an oral fluoropyrimidine that is increasingly used in Western countries for the treatment of metastatic colorectal cancer (mCRC). We conducted a non-inferiority meta-analysis on the efficacy of S-1-based therapy versus 5-fluorouracil (5-FU)- or capecitabine-based therapy in the treatment of patients with mCRC. METHODS: MEDLINE, Embase, the Cochrane Central Register of Controlled Trials and Opengrey were searched for randomised clinical trials until May 2021. Data were extracted for progression-free survival (PFS), overall survival (OS), objective response rate (ORR) and adverse events. Pooled effect estimates, stratified by treatment line, with corresponding 99% confidence intervals (CI) were presented. For PFS, a pre-defined non-inferiority margin (ΔNI) of 1.25 was selected. RESULTS: Ten studies (n = 2117) were included, of which six studies reported PFS and OS data and 10 studies reported ORR data. S-1-based therapy was shown to be non-inferior to 5-FU/capecitabine-based therapy in terms of PFS (HRtotal 0.95, 99% CI 0.83-1.08) with its CI upper limit well below ΔNI, and at least as efficacious in terms of OS (HRtotal 0.93, 99% CI 0.81-1.07), and ORR (RRtotal 1.06, 99% CI 0.90-1.24). CONCLUSIONS: S-1-based therapy is non-inferior to 5-FU/capecitabine-based therapy in the treatment of mCRC regarding PFS and at least as efficacious as 5-FU/capecitabine-based therapy in terms of ORR and OS. These data support the use of S-1 in mCRC patients who are intolerant to 5-FU/capecitabine-based treatment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Derksen JWG, Smit KC, May AM, et al. Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer. Eur J Cancer. 2022. PMID: 35279472. doi:10.1016/j.ejca.2022.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。